Building Upon Solid Foundations

Innoviva’s royalty portfolio is anchored by its flagship partnership with Glaxo Group Limited (GSK), which include RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.


Approved for COPD/Asthma and marketed globally.


Milestone Moments:

RELVAR®/BREO® ELLIPTA® is under review by other regulatory agencies globally.

Learn more about asthma from

Royalty Structure

Innoviva receives royalties on net sales of RELVAR®/BREO® ELLIPTA® of 15% for the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion.

In addition, Innoviva retains a 15% economic interest in future payments made by GSK for earlier-stage programs.